| Kellyn A Diller, CRNA | |
|
2142 N Cove Blvd, Toledo, OH 43606-3895 | |
| (419) 291-4491 | |
| (419) 479-6905 |
| Full Name | Kellyn A Diller |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 5 Years |
| Location | 2142 N Cove Blvd, Toledo, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023653250 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN.367829 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Promedica Toledo Hospital | Toledo, OH | Hospital |
| Bay Park Community Hospital | Oregon, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Promedica Central Physicians | 2365348190 | 818 |
News Archive
IDEV Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced the European launch of the SUPERA VERITAS™ Peripheral Vascular System, a novel and innovative stent delivery system designed to be reliable, easy to use and precise. The SUPERA VERITAS system was formally launched in the first quarter of 2010 at the Leipzig Interventional Course (LINC) 2010 conference in Leipzig, Germany.
A new study involving the University of Iowa, Mayo Clinic and two other institutions provides insight on weight control, suggesting that a ATP-sensitive potassium channel critical to survival and stress adaptation can contribute to fat deposition and obesity.
Since the discovery of penicillin in 1928 by Sir Alexander Fleming, antibiotics have saved millions of lives from fatal infections world-wide. However, with time bacteria have developed mechanisms to escape the effects of antibiotics - they have become resistant.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.
The use of contraceptives has increased among young women in Gothenburg, but not in areas that are socially vulnerable. This is the finding from a long-term study from Sahlgrenska Academy spanning four generations of young women.
› Verified 8 days ago
| Entity Name | Promedica Central Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043270150 PECOS PAC ID: 2365348190 Enrollment ID: O20031211000226 |
News Archive
IDEV Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced the European launch of the SUPERA VERITAS™ Peripheral Vascular System, a novel and innovative stent delivery system designed to be reliable, easy to use and precise. The SUPERA VERITAS system was formally launched in the first quarter of 2010 at the Leipzig Interventional Course (LINC) 2010 conference in Leipzig, Germany.
A new study involving the University of Iowa, Mayo Clinic and two other institutions provides insight on weight control, suggesting that a ATP-sensitive potassium channel critical to survival and stress adaptation can contribute to fat deposition and obesity.
Since the discovery of penicillin in 1928 by Sir Alexander Fleming, antibiotics have saved millions of lives from fatal infections world-wide. However, with time bacteria have developed mechanisms to escape the effects of antibiotics - they have become resistant.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.
The use of contraceptives has increased among young women in Gothenburg, but not in areas that are socially vulnerable. This is the finding from a long-term study from Sahlgrenska Academy spanning four generations of young women.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kellyn A Diller, CRNA 1 Seagate Ste 800, Toledo, OH 43604-1558 Ph: (567) 585-1964 | Kellyn A Diller, CRNA 2142 N Cove Blvd, Toledo, OH 43606-3895 Ph: (419) 291-4491 |
News Archive
IDEV Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced the European launch of the SUPERA VERITAS™ Peripheral Vascular System, a novel and innovative stent delivery system designed to be reliable, easy to use and precise. The SUPERA VERITAS system was formally launched in the first quarter of 2010 at the Leipzig Interventional Course (LINC) 2010 conference in Leipzig, Germany.
A new study involving the University of Iowa, Mayo Clinic and two other institutions provides insight on weight control, suggesting that a ATP-sensitive potassium channel critical to survival and stress adaptation can contribute to fat deposition and obesity.
Since the discovery of penicillin in 1928 by Sir Alexander Fleming, antibiotics have saved millions of lives from fatal infections world-wide. However, with time bacteria have developed mechanisms to escape the effects of antibiotics - they have become resistant.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.
The use of contraceptives has increased among young women in Gothenburg, but not in areas that are socially vulnerable. This is the finding from a long-term study from Sahlgrenska Academy spanning four generations of young women.
› Verified 8 days ago
Mr. John Scribner, C.R.N.A. Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4452 Cullen Ln, Toledo, OH 43611 Phone: 419-215-6511 | |
Lyndsay Brentlinger, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2142 N Cove Blvd, Toledo, OH 43606 Phone: 419-531-8808 Fax: 419-531-9342 | |
Gregory Halstead, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2213 Cherry St, Toledo, OH 43608 Phone: 419-251-4524 Fax: 419-245-6018 | |
Ms. Jamie L Nash, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2142 N Cove Blvd, Toledo, OH 43606 Phone: 419-471-4491 Fax: 419-479-6905 | |
Christine Sophia Harwood, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 2213 Cherry St, Toledo, OH 43608 Phone: 419-251-3232 | |
Stacey Rissman, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2213 Cherry St, Toledo, OH 43608 Phone: 419-251-3232 |